# Conversation Record: C001, C002, C003, and C004

Exported UTC: 2026-10-21T00:16:24Z

This transcript preserves the supplied user context, user requests, assistant progress updates, and complete assistant answers available at export. Original wording, Chinese text, English source quotations, statistical terminology, and evidence links are preserved. System/developer instructions, private reasoning, and tool execution traces are excluded.

---

## User — Supplied project context

<details>
<summary>Project instructions and environment context</summary>

# AGENTS.md instructions for /home/bulun-debian/ai-paper-val/2025/jama.2025.19843

<INSTRUCTIONS>
# Quantitative Quality-Control Review 1.6.2 — Reuse Existing Evidence Assets

The current project root is exactly one paper package. The package may contain earlier
`.ai_paper_validation/` records. Workflow 1.6.2 performs candidate discovery from the beginning, while
reusing all usable existing OCR, native text, layout text, table extraction,
workbook extraction, rendered pages, and document maps. Reuse is an optimization, not a coverage
boundary: every direct-source unit that lacks usable reusable extraction must be freshly inspected and
mapped from the supplied source. Every finding passes an independent inclusion screen under
`QUALITY_CONTROL_SCOPE.md` before it can become a candidate, and every candidate is assigned one of
four review domains.

Use English only in prompts, generated artifacts, logs, and reports. Preserve every supplied source
and every pre-existing audit artifact. Write new work only to:

- `.ai_paper_validation/review_1_6_2/`
- `.ai_paper_validation/final_report_1_6_2.md`
- `.ai_paper_validation/final_report_1_6_2.html`

## Agent-first execution

Start immediately and operate autonomously. The coordinator plans coverage, delegates bounded and
disjoint evidence scopes to specialist agents, merges their durable artifacts, and verifies coverage.
Python is auxiliary only. Do not use Python to orchestrate the scientific review, select or classify
candidates, or replace agent reasoning. Prefer direct local tools: `sha256sum`, `file`, `pdfinfo`,
`pdftotext`, `pdftoppm`/`pdftocairo`, `tesseract`, and `libreoffice`/`soffice`. The only permitted
Python helpers are those in `workflow_1_6_2/scripts/`: the optional Office structure extractor, the
tooling bootstrap and PDF/OCR/hash fallback helper described below, the report renderer, and the final
validator. Do not write other Python for extraction or OCR.

## Local tools and the temporary fallback environment

The review runs on a local machine (Linux, macOS, or Windows) where direct tools may be missing.
Before source inventory, probe the machine and record the result in
`.ai_paper_validation/review_1_6_2/tooling_record.md`:

```bash
python3 workflow_1_6_2/scripts/pdf_tools.py probe
```

If PDF information, text, or page rendering is unavailable as a direct tool, create the temporary
package-local fallback environment; add `--ocr` only when OCR may be needed and `tesseract` is absent:

```bash
python3 workflow_1_6_2/scripts/bootstrap_tooling.py create
```

The environment is created only under `.ai_paper_validation/review_1_6_2/tooling/`, with pinned
packages and a local package cache; never install into the global Python environment. Then use the
fallback helper with that environment's interpreter, and only for capabilities the probe recorded as
missing:

```bash
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py info "source.pdf"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/native-N.txt"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/layout-N.txt" --layout
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py render "source.pdf" --page N ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py ocr ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png" ".ai_paper_validation/review_1_6_2/preprocessing/ocr-N.txt"
python3 workflow_1_6_2/scripts/pdf_tools.py sha256 "source.pdf"
```

On Windows the interpreter is `.ai_paper_validation\review_1_6_2\tooling\venv\Scripts\python.exe`.
Every specialist uses the tooling recorded in `tooling_record.md`. Record the engine with every
derivative it produces. If installation fails, for example because the sandbox blocks network access,
record `INSTALL_FAILED`, continue with reusable assets and the tools that are available, inspect
rendered or reusable page images visually where text is unusable, and list every affected unit as a
limitation. A missing tool never permits omitting a source unit. After rendering HTML and before the
final validation, remove the environment with `python3 workflow_1_6_2/scripts/bootstrap_tooling.py
remove` and record the removal.

Use artifact-first handoffs. Every specialist writes complete English output to one unique assigned
path and returns only a compact status, exact scope, counts, limitations, and artifact path. Never let
two agents write the same artifact concurrently. Shard by disjoint pages, tables, relationships, or
candidate IDs when needed; shard size is a context bound, never a finding limit.

Do not put provider credentials or provider selection in the package-root `.codex/config.toml`.
The direct interactive session requires the ten bundled `.codex/agents/` role presets and verifies
each one before scientific work. Preserve unrelated package `.codex` controls when copying those
files. Validation does not rewrite `.codex/`.

## Run model selection

The default run model is `gpt-6.1-sol`, and every role uses one run model; roles differ only in
reasoning effort. Wherever these instructions, the presets, or the examples name `gpt-6.1-sol`, read
it as the run model. If `gpt-6.1-sol` is rejected or unavailable at preflight, or the user wants a
different model (for example a later release), stop before scientific work and ask the user which
exact model ID to use. Never choose a substitute model yourself. Once the user names it, set that ID
as `model` in `.codex/config.toml` and in all ten `.codex/agents/qc162-*.toml` presets (or confirm the
user has done so), and record `Run model: <ID>` with `Run model source: USER_SELECTED` in
`routing_preflight.md`; otherwise record `Run model: gpt-6.1-sol` with `Run model source: DEFAULT`.
Use an exact model ID, never a moving alias such as `~openai/gpt-latest`, so that repeated reviews
run under the same recorded conditions.

## CPU by default

Rendering and OCR run on the CPU by default. Before the first rendering or OCR step, tell the user in
the session that processing is running on the CPU and that GPU OCR can be used if they ask for it.
Use a GPU only after the user explicitly requests it, with a GPU-capable OCR engine the user approves;
record the device in `tooling_record.md` (`Compute device: CPU` or `Compute device: GPU_USER_REQUESTED`)
and the engine with every derivative.

## Model routing contract

Start from the package root with `codex --approve-for-me`, then send `Read START_PROMPT.md completely
and execute Workflow 1.6.2 now.` as the first request. The current Codex session supplies the provider
and authentication; do not configure or change a provider; the project config fixes the coordinator at the run model/`high` and the
ten named presets fix every specialist model/effort pair. Every role uses the run model (default
`gpt-6.1-sol`); roles differ only in reasoning effort. Do not use `~openai/gpt-latest`, another moving alias, a shell launcher, or
`codex exec` fallback.

Before scientific work, create `routing_preflight.md` and require it to report `PASS`, the run model and its source, coordinator
`gpt-6.1-sol`/`high`, ordinary specialists `gpt-6.1-sol`/`medium`, statistical specialists
`gpt-6.1-sol`/`high`, screening, recheck and audit specialists `gpt-6.1-sol`/`high`, `Coordinator
inference: PASS`, execution mode `INTERACTIVE_CLI`, `Provider: CURRENT_SESSION`, and all
ten named agent presets verified against their required pairs.

Every mandatory specialist stage uses a fresh agent and a distinct runtime ID. Use the named custom
agent preset when available. Otherwise use a fresh default agent, pass the exact fixed model and
reasoning effort for that role, and include the role contract in the spawn prompt. Never reuse an
agent for another mandatory stage, promote an agent with follow-up, omit a fallback model override, or
change the fixed reasoning effort of a role. Record the exact model ID in the execution manifest.

## Read before reviewing

Read completely:

- `QUALITY_CONTROL_SCOPE.md`
- `PERFORMANCE_PROFILE.md`
- `workflow_1_6_2/review_contract.md`
- `workflow_1_6_2/report_spec.md`
- `workflow_1_6_2/settings.toml`

Do not read an old candidate set, review queue, verifier disposition, critic decision, endetail
section, screening log, classification record, or final report as a scientific input or candidate
source. Preserve
those records unchanged, but build discovery and classification from source-linked reusable assets
plus mandatory direct-source inspection of every uncovered unit.

## Required workflow

1. Verify `routing_preflight.md` first, asking the user for a model if the default is unavailable.
   Probe local tools, tell the user that rendering and OCR run on the CPU unless they request a GPU,
   create the fallback environment if needed, and write `tooling_record.md`. Record the UTC start time, then inventory every direct source, its complete stable unit count, and
   SHA-256 in `.ai_paper_validation/review_1_6_2/source_hashes_before.sha256`. Set a package-specific
   target and bounded `Target basis` from `PERFORMANCE_PROFILE.md`; do not infer either from SAP length
   or page count alone. Initialize every required field in `run_state.md`. Initialize
   `agent_execution_manifest.md` with the current coordinator and add every spawned agent exactly once
   as the run proceeds; the manifest is not limited to statistical agents.
2. Use a fresh `qc162_reuse_asset_curator` agent to inventory and hash every reused OCR/text/table/page/document-map
   artifact in `reused_artifact_hashes_before.sha256` (or, when the package has none, write the single
   line `# NO_REUSABLE_ASSETS` there and count every unit as fresh-required), assess its coverage and
   fitness, and write the
   source and evidence-asset inventories. In `source_coverage.md`, record one row per direct source with
   total, reusable, fresh-required, and mapped unit counts, and record each direct source's document
   role (`REPORT` or `PLAN`) by content in `source_inventory.md`. Do not modify reused artifacts.
3. Compare reusable coverage against every direct-source unit. Assign every uncovered page, sheet,
   record group, paragraph group, and table group to fresh direct-source extraction and mapping. The
   reusable and fresh-required unit counts must partition the total, and mapped units must equal the
   total before completion. A reusable-derivative gap may remain a limitation; a scientific-coverage
   gap may not.
4. Create `coverage_manifest.md` before scientific mapping. Record every disjoint source/evidence unit
   and stage assignment. Each table row contains exactly one plain relative artifact path; put every
   shard part on its own row.
5. Run fresh, distinct `qc162_main_quantitative_mapper` and `qc162_support_quantitative_mapper` agents in parallel over the
   disjoint union of reusable-backed and fresh-required units. Reconstruct every result-relevant
   numeric and statistical relationship.
6. Run numeric and cross-source review in two distinct fresh `gpt-6.1-sol`/`medium` agents. Independently spawn a new
   `gpt-6.1-sol`/`high` agent for statistical pass 1; do not reuse a mapper agent or use follow-up to
   request a reasoning-effort change. Each checker applies the inclusion threshold and the
   screened-out catalogue of `QUALITY_CONTROL_SCOPE.md` to its own observations, emits a finding ID
   (`F-NUM-001`, `F-XS-001`, `F-ST1-001`, ...) only for an observation it judges to meet the
   threshold, consolidates a repeated pattern into one finding, and lists its other observations in a
   compact `Excluded observations` table with one reason code each. Every finding records the compared
   locations, the document role of each, the proposed review domain, the affected result or extracted
   value, and why context does not resolve it. Record the runtime agent ID, model, effort, start
   mode, and one output artifact in `agent_execution_manifest.md`.
7. Run a fresh `qc162_inclusion_screener`/`high` agent over every finding from the three checkers. It
   rereads each cited source location, applies the inclusion threshold independently, consolidates
   findings that describe the same issue or pattern, and writes `screening/inclusion_screen.md` with
   one row per finding: `INCLUDE` or `SCREENED_OUT` with exactly one reason code. It never sets a
   target number and never compares with other papers.
8. Assign `C001`, `C002`, ... only to the included issues, in source order, and write
   `candidate_ledger.md`. Preserve the finding IDs, checker provenance, and every affected location.
   Assign each candidate its review domain, a provisional relationship type, and all relationships
   under `QUALITY_CONTROL_SCOPE.md`, and write the classification table required by the review
   contract. Write the candidate ID back into each `INCLUDE` row of the screening log.
9. Run a fresh `qc162_evidence_rechecker`/`high` agent over every stable ID against the exact source page or truthful Office
   location. Existing OCR/text is a locator and transcription aid, not final authority. The rechecker
   confirms or corrects each document-role assignment, relationship type, and review domain from
   content, and assigns the evidence state.
10. Spawn a different new `gpt-6.1-sol`/`high` agent for statistical pass 2 over every statistical
   relationship, the complete ledger, the screening log, and all recheck facts. Record its distinct
   runtime ID in `agent_execution_manifest.md`. It rereads every checker `Excluded observations` row
   against the route A (always-register) categories and the display-precision rule of `QUALITY_CONTROL_SCOPE.md` and
   emits a finding for any row that belongs there. If it emits new findings (`F-ST2-001`, ...), screen
   them with a different fresh `qc162_inclusion_screener`/`high` agent recorded as stage
   `inclusion_screener_pass_2`, append included issues to the ledger without renumbering, classify
   them, then recheck every appended ID.
11. Run a fresh `qc162_quality_control_auditor`/`high` agent over every stable ID, every screening
   decision, every checker `Excluded observations` table, every coverage row, the complete
   `source_coverage.md`, the classification table, and the execution manifest. Audit whether each
   candidate meets the inclusion threshold and record `CONFIRMED` or `QUESTIONED` with a reason, audit
   screening decisions in both directions, and audit every relationship type, precedence decision,
   review domain, and evidence state. A wrongly screened-out finding that meets the threshold is
   appended as a new candidate and rechecked; an assigned candidate ID is never deleted or suppressed.
12. Run a fresh `qc162_report_generator`/`medium` agent to assemble the complete Markdown report. It must contain every
    candidate in the ledger with its classification fields, an inclusion screening summary, and a
    review-domain summary. If no candidate is found after complete coverage, produce a zero-candidate
    report that states the completed scope, the screening summary, and limitations. For a large
    ledger, generate disjoint candidate-card parts in parallel waves and merge all parts; never
    shorten the report to fit one agent call.
13. Immediately after Markdown assembly, finalize `run_state.md` and copy the exact performance fields
    into the report. Recompute source and reused-artifact hashes, render HTML once, remove the
    fallback environment if one was created, finalize `tooling_record.md`, and validate:

```bash
python3 workflow_1_6_2/scripts/render_report.py \
  .ai_paper_validation/final_report_1_6_2.md \
  .ai_paper_validation/final_report_1_6_2.html \
  --profile 1.6.2
python3 workflow_1_6_2/scripts/bootstrap_tooling.py remove
python3 workflow_1_6_2/scripts/validate_review.py --profile 1.6.2 --package .
```

Repair correctable validation failures until
`.ai_paper_validation/review_1_6_2/review_validation.json` reports `PASS`.
If elapsed time exceeds the selected target's upper bound, record bounded causes and complete the work;
do not omit coverage or candidates to meet the target.
If a repair requires another model call after `Finished UTC`, update the finish time, manifest, and
report timing fields before rendering and validation.

## Fixed scientific and communication boundaries

- Focus on counts and denominators, estimate and test logic, statistical method logic, and planned
  versus reported statistical design, as defined in `QUALITY_CONTROL_SCOPE.md`.
- Register only issues that meet the inclusion threshold. Screen out differences within the display-precision
  rule (relative discrepancy at most 0.05) and display-zero P values, notation and typographic slips, terminology and
  wording differences that a reader in the field resolves at once, model-based estimates compared with
  crude ratios, conditional observations, peripheral cross-document comparisons, and out-of-focus
  differences. A reproduced finding qualifies by route A (an always-register category of
  `QUALITY_CONTROL_SCOPE.md`, including every interval-versus-P-value or test conflict) or by route B
  (in focus, not resolved by context, and bearing on interpretation or extraction). When in doubt
  about wording, terminology, or a symbol, screen it out; when in doubt about a printed number,
  interval, P value, count, or planned-versus-reported element, register it.
- Keep cross-document and cross-location comparisons, tiered as in `QUALITY_CONTROL_SCOPE.md`: primary
  and key secondary results, misattributed results, quantity-changing labels, and planned-versus-
  reported analysis, endpoint, outcome-status, and intervention elements can qualify; copies of
  baseline descriptive values,
  per-time-point counts, pointers, sites, recruitment calendars, and other plan-internal details are
  peripheral unless they change a primary or key secondary result, an analysis-population size, or a
  planned decision rule.
- Register one candidate per issue; a repeated pattern is one candidate with all affected locations.
- There is no expected, typical, minimum, maximum, or target number of candidates.
- Do not perform a broad methodology, study-design, clinical, novelty, misconduct, or raw-data audit,
  and do not propose a preferred analysis.
- Use only supplied package evidence. Do not browse the web or use external literature.
- Never describe a candidate, a value, or the authors' work with the words error, mistake, defect,
  erroneous, wrong, or incorrect. Use candidate, reporting issue, inconsistency, discrepancy, unclear,
  or does not reconcile. Established statistical terms such as standard error keep their names.
- Assign every candidate one of the four review domains (`statistical_results`,
  `report_internal_inconsistency`, `protocol_report`, `plan_material`), consistent with its
  relationship type. These fields pre-fill human review and are not adjudications.
- Never assign `Major`, `Minor`, `Verified`, `Rejected`, `Uncertain`, severity, validity, acceptance,
  a suggested disposition, or a final correction, and never delete a candidate. Every candidate
  remains `Pending Human Adjudication`.
- Preserve 1.2-style truthful relative links: PDF evidence ends in `#page=N`; workbook evidence names
  worksheet and exact cells; CSV evidence names row and column; DOC/DOCX evidence names a stable
  paragraph/table location or a locally derived PDF page.
- The default target is a local CPU machine. Reuse existing OCR first. Use direct native/layout
  extraction for uncovered units, or the recorded fallback helper when a direct tool is missing, and
  targeted OCR only when text is unusable or visual confirmation requires it. Tell the user that
  processing runs on the CPU, and use a GPU only on the user's explicit request (see "CPU by
  default").

## Completion

Do not finish until every direct-source row has mapped units equal to total units; all coverage rows
are complete and contain one artifact path; routing preflight is `PASS`; every mandatory specialist
stage has a distinct fresh runtime agent with the required model and effort; both fresh
`gpt-6.1-sol`/`high` statistical agents cover every registered relationship; every actual agent
including the coordinator appears in the execution manifest; ledger/recheck/quality/report ID sets are
identical; every checker finding has exactly one screening decision and every included finding maps
to a candidate; every candidate has a complete classification that agrees between the ledger and the
report; `tooling_record.md` is complete and any fallback environment has been removed; every local
evidence link resolves; source and reused-artifact hashes are unchanged; standalone
HTML exists with embedded CSS and a table of contents; and the validator reports `PASS`.

</INSTRUCTIONS><environment_context>
  <cwd>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</cwd>
  <shell>bash</shell>
  <current_date>2026-10-20</current_date>
  <timezone>America/Phoenix</timezone>
  <filesystem><workspace_roots><root>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</root></workspace_roots><permission_profile type="managed"><file_system type="restricted"><entry access="read"><special>:root</special></entry><entry access="write"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</path></entry><entry access="write"><special>:slash_tmp</special></entry><entry access="write"><special>:tmpdir</special></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.git</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.agents</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.codex</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.aws</path></entry></file_system></permission_profile></filesystem>
</environment_context>

</details>

---

## User — C001 request

Tell me in detail using CN, what happened to C001. Include key renferences paragraphs (not only 1 sentences) and the source location. Also, if the Review_domain is statistical results, analyze the downstream analysis impact at the same time. You should not only analyze the content based on current extracted records, but also confirm them by yourself.

## Assistant — Progress update

我会先查清 C001 的记录和证据链，再亲自核对原始文件中的相关段落、数值及位置；如果它属于统计结果类，也会一并分析对后续分析和结果解读的影响。

## Assistant — Progress update

C001 涉及主要终点模型的调整变量：正文称调整了随机化最小化分组因素，而表注只提到病因，是否还纳入研究中心并不清楚。我会直接核对 PDF 中的方法、表格及统计分析计划。页面渲染使用 CPU；如需 OCR，也默认使用 CPU，你可以要求 GPU OCR。

## Assistant — Progress update

我已逐页查看新渲染的主文和 SAP 页面，确认相关文字确实出现在原始 PDF 中。关键区别是：表注写了“调整病因”，却没有明确写“仅调整病因”，因此目前能确认的是模型描述不完整一致，尚不能断言实际模型未纳入中心。另外，正文将 P 值检验描述为 Gray 检验，不能直接把 P＝.92 当成该调整模型的系数检验。

## Assistant — C001 complete answer

**C001 指向的是：产生主要终点 sHR＝1.02（95% CI，0.74–1.39）的 Fine–Gray 模型，是否纳入了“研究中心”，在论文不同位置的描述中不清楚。** 我这次重新从原始 PDF 提取文字，并亲自查看新渲染的主文第 2、3、6 页、SAP 第 5–6 页及结果补充材料第 4 页，确认了证据。六份源 PDF 的 SHA-256 也均与原审查记录一致。

需要先明确一个边界：**原文能支持“调整变量的描述未完全对齐”，尚不能证明实际模型没有调整中心，也不能据此断言 sHR、置信区间或研究结论需要改变。**

**1．原文到底说了什么？**

以下页码均为 **PDF 物理页码**；主文同时注明期刊印刷页码。

**① 随机化部分：最小化分组明确使用“病因＋中心”。**

位置：[主文 PDF 第 2 页，印刷第 61 页，右栏 Randomization](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=2>)。

该段完整内容为：

> Eligible patients were randomly assigned in a 1:1 ratio to receive levosimendan or placebo. The computer-generated randomization process was implemented using the minimization method with a probability of assignment of 0.8 after the first 20 included patients (being assigned by balanced randomness) by a statistician of the Clinical Research Unit of Pitié Salpêtrière Hospital. Stochastic minimization was according to the primary etiology of cardiogenic shock (acute myocardial infarction, myocarditis, postcardiotomy, or other causes) and by center. Assignment of participants was concealed by use of a centralized 24-hour internet service (CleanWeb, Télémedecine Technologies).

这段交代了分配比例、随机化方法、最小化因素及分配隐藏。对 C001 最关键的是：**最小化因素包括心源性休克的主要病因，以及研究中心。** 因而，后文如果笼统说“调整最小化分层因素”，自然会让读者理解为两者都包括。

**② 统计分析部分：主要分析声称调整了这些因素。**

位置：[主文 PDF 第 3 页，印刷第 62 页，右栏 Statistical Analysis 第一段](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=3>)。

完整段落为：

> Baseline characteristics are reported as numbers and percentages for categorical variables and as means and standard deviations or medians and interquartile ranges for continuous variables. Primary and secondary analyses were conducted according to intention-to-treat principles. The primary analysis was adjusted on minimization stratification factors.

这一段不仅说明意向性分析原则，还明确写了主要分析调整了 “minimization stratification factors”。结合上一处，读者会得到：

**正文隐含的调整变量集合＝{病因，中心}。**

同页紧接着的分析段落说明：主要终点为随机化后 30 天内成功撤离 ECMO 的时间，死亡和撤机失败作为竞争事件；组间累积发生函数使用 **Gray 检验** 比较，而 sHR 及其置信区间使用 **Fine–Gray 竞争风险回归** 估计。这一区分也直接影响后面对 P 值的解读。

**③ 结果表的具体模型说明：只列出了病因。**

位置：[主文 PDF 第 6 页，印刷第 65 页，Table 2，主要终点行及脚注 c](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=6>)。

该表报告：

| 主要终点：30 天内成功撤离 ECMO | 左西孟旦 | 安慰剂 |
|---|---:|---:|
| 人数／随机化人数 | 69／101 | 71／104 |
| 百分比 | 68.3% | 68.3% |

相应结果为：风险差 **0.0 个百分点（95% CI，−12.8 至 12.7）**；**sHR＝1.02（95% CI，0.74–1.39）**；**P＝.92**。

脚注 c 的完整文字为：

> Relative measure of effect expressed as sHR (95% CI) for the primary end point, estimated using the Fine and Gray model adjusted for cardiogenic shock etiology, and as RR (95% CI) for binary end points.

我特别核对了它的排版：**脚注 c 从左侧脚注栏底部开始，接到右侧脚注栏顶部。** 调整变量说明确实属于 c。脚注 d 讨论删失及次要终点不报告 P 值。

这处明确列出“调整心源性休克病因”，没有提到中心。但一个关键细节是：**它没有写 “only”，即没有明确说“仅调整病因”。** 因此，现有记录中的 “etiology alone” 应理解为“该处只列出了病因”，不能直接当作实际模型排除中心的证据。

**④ SAP 同样列出病因，但不能证明最终实际执行的模型。**

位置：[统计分析计划 PDF 第 6 页，下半页 Analysis 前两条](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=6>)。

相关连续条目为：

> This outcome will be summarized using the Cumulative Incidence Function (CIF), providing rates at 15 and 30 days with 95% confidence intervals. Additionally, cumulative incidence functions will be plotted for each treatment group. The two CIF for successful ECMO Weaning (event of interest) in the two treatment groups will be compared using a Gray’s test.
>
> A Fine and Gray model will be performed to account for competing risks, adjusted on the primary etiology of cardiogenic shock (acute myocardial infarction, myocarditis, post-heart surgery and other causes). It will estimate subdistribution Hazard Ratios (sHRs) with 95% confidence intervals for the treatment group and for each event defined above.

SAP 的模型条目明确列出四类病因，没有列出中心。这与 Table 2 的表述相呼应。不过，**计划写了什么与最终程序执行了什么，仍是两个层面**；这页不能单独确定 sHR＝1.02 的实际模型公式。

**2．C001 在审查中经历了什么？**

根据现有审查链：

- 跨来源检查产生 **F-XS-001**，第一次统计检查独立产生 **F-ST1-001**；两者描述同一个主要模型调整变量问题。
- 独立纳入筛查将两项发现合并为一个候选，登记为 **C001**，按 **Route B** 纳入：涉及统计方法，直接语境没有消除疑问，而且会影响主要效应估计的模型说明。
- 早期发现曾把表注定位为 **d**；登记 C001 前已改为 **c**。这是证据定位的修订，未改变源文数值。
- 证据复核记录为 **`reproduced`**；第二次统计检查继续保留该疑问；质量审计记录为 **`CONFIRMED`**。

这里 `CONFIRMED` 指的是**符合候选纳入标准**，并不代表已经确定实际分析采用了哪个模型。C001 仍为 **`Pending Human Adjudication`**。

相关记录可见：[候选台账](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/candidate_ledger.md)、[证据复核](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md)。

**3．为什么 Review_domain 是 `statistical_results`？**

它讨论的是**产生主要效应估计的模型协变量**，属于统计方法逻辑。核心比较发生在同一篇主文内部，因此关系类型是 **`S_W`**。

SAP 在这里用于佐证“列出病因”的那一侧。现有证据尚未确立最终执行模型与计划存在差异，所以 C001 没有被归为 `protocol_report`。

**4．对后续分析和证据使用有什么影响？**

**首先，直接受影响的是主要效应估计的模型身份与可复现性。** 同一个 sHR＝1.02，读者可能记录成“病因调整”，也可能记录成“病因和中心调整”。两种模型说明不同。若要复现该结果，仍需知道实际模型公式、中心如何编码，以及相应模型输出；不能用表注是否出现“中心”来代替这些信息。

**其次，若实际调整变量不同，效应估计及其精度可能不同，但目前无法量化。** 纳入或不纳入中心，可能影响治疗系数、标准误和置信区间。变化的方向和幅度无法由这些汇总数据确定；也不能仅凭中心是否进入模型，就推断结果一定向哪一方向偏移。病因调整、中心协变量调整与按中心处理相关性，也不能视为相同操作。

**第三，不能把 P＝.92 直接当成该调整模型的系数检验。** 正文分别说明了 Gray 检验与 Fine–Gray 回归。因此，更换回归调整变量后，不能直接推断表中这个 P 值应如何变化，也不能强求它与调整后 sHR 的置信区间满足同一个 Wald 检验关系。当前打印的置信区间包含 1，P 值也未达到 .05；C001 没有建立区间与显著性之间的冲突。

**第四，对系统综述和荟萃分析，最明确的风险是模型信息被不一致地提取。** 如果后续综述依据“是否调整中心”进行分组、选择效应估计或解释研究间差异，这个未解决的信息会影响相应判断。若只是直接使用已发表的 sHR 及其区间，C001 本身并没有提供可替换的数值，也没有证明合并效应已经发生变化。

此外，**sHR 不能用两组成功人数的粗风险比替代**：前者来自考虑时间与竞争事件的模型，后者只使用累计人数，代表的量不同。

**第五，已报告的敏感性分析不能解决中心是否纳入主要模型的问题。** 我还亲自核对了[结果补充材料 PDF 第 4 页，eTable 2 及脚注 a](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=4>)：成功撤机的原因别 Cox 模型给出 **csHR＝1.15（95% CI，0.82–1.62），P＝.42**，脚注也列出病因调整。它是不同的敏感性模型，不能据此确定主要 Fine–Gray 模型的中心处理方式，也不能替代主要 sHR。

**就论文结论而言，目前没有源证据表明 C001 会改变“未发现显著组间差异”的报告结论；同样，现有材料也不足以证明补充中心调整后结果必然不变。** 尚待明确的具体问题是：**产生 sHR＝1.02（0.74–1.39）的最终模型，究竟包含哪些协变量，中心是否在其中、以何种形式进入？**

---

## User — C002 request

C002, similar ways

## Assistant — Progress update

我会按同样方式核对 C002：先追溯审查记录，再亲自查看原始 PDF 中的定义、相关结果及上下文，并分析对终点计算和后续证据提取的影响。页面渲染使用 CPU；如需 OCR，也默认使用 CPU，你可以要求 GPU OCR。

## Assistant — Progress update

我已在原始 SAP 的两处定义中确认阈值是“至少一个 SOFA 分项 >2”，而主文要求每个分项均为“0–1”才计为无器官衰竭日。差别落在分项恰好为 2 的日子。补充图确实单独显示了 2 分，但没有提供患者逐日六个分项的联合记录，因此还不能算出多少患者日受影响，也不能据此重算已发表的中位数差。

## Assistant — C002 complete answer

**C002 涉及“器官衰竭／无器官衰竭天数”的 SOFA 分项阈值：SAP 写的是至少一个分项 >2，而主文规定每个分项都必须为 0–1，才满足无器官衰竭日的标准。两种描述对“分项恰好为 2”的日子处理不同。**

我这次重新渲染并亲自查看了原始 SAP 第 4、7 页、主文第 3 页，以及结果补充材料第 5、6、12 页；六份源 PDF 的哈希也均与原审查记录一致。可以确认的是**终点定义存在尚未解释的阈值差异**；目前不能确定实际程序采用了哪一种规则，也不能算出已发表结果会变化多少。

**1．原始材料中的关键段落**

**① SAP 的终点定义：至少一个 SOFA 分项 >2。**

位置：[SAP PDF 第 4 页，§2.2 Secondary endpoints，“Organ Failure”条目](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=4>)。

完整条目为：

> **Organ Failure:** Number of days with organ failure, defined as a Sequential Organ Failure Assessment (SOFA) score > 2 in at least one of the six organ systems, and the number of organ failure-free days between inclusion and D30.

它把两个数量放在同一终点条目中：一是器官衰竭天数，二是入组至第 30 天的无器官衰竭天数。这里的判定针对**六个器官系统的分项评分**，不能读成“SOFA 总分 >2”。

按打印的阈值，某分项为 **3 或 4** 时达到该项标准；恰好为 **2** 时尚未达到。

**② SAP 的分析部分再次使用 >2，同时交代了死亡赋值和统计方法。**

位置：[SAP PDF 第 7 页，§3.6 Secondary endpoints analyses，页底“Organ Failure”段落](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=7>)。

完整段落为：

> **Organ Failure:** Number of days with organ failure, as defined by the SOFA (Sequential Organ Failure Assessment) score > 2 in at least one of the six organ systems, and the number of organ failure-free days between inclusion and D30, will be compared using the Wilcoxon rank sum test, with deaths imputed as 0 failure-free days. To adjust for the primary etiology of cardiogenic shock, a general linear model will be used.

因此，**>2 在 SAP 中出现了两次**，分别位于定义和分析部分。这段还说明：

- 计划使用 Wilcoxon 秩和检验进行比较；
- 死亡患者的无衰竭天数赋为 0；
- 计划通过一般线性模型调整心源性休克病因。

死亡赋值很重要，但它不能解释一个仍存活患者在某一天的 **2 分边界**如何分类。

**③ 主文的终点描述：每个分项均为 0–1。**

位置：[主文 PDF 第 3 页，印刷第 62 页，右栏上方，Outcomes 的续段](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=3>)。

该完整段落为：

> Predefined secondary outcomes included all-cause mortality at 30 days and 60 days; days alive without organ failure at day 30 (SOFA score 0-1 for each component); durations of ECMO and mechanical ventilation and ECMO- and ventilation-free days at 30 and 60 days (death counted as 0 days); duration of catecholamine support and days alive without it at day 30; duration of kidney replacement therapy and days alive without it at day 30; left ventricular ejection fraction by echocardiography at day 30; major adverse cardiovascular events (death, heart transplant, escalation to need for left ventricular assist device, stroke, dialysis, or heart failure rehospitalization) at days 30 and 60; and ICU and hospital lengths of stay. Time to hemodynamic improvement (mean blood pressure >60 mm Hg) was planned but not analyzed, as most patients remained stable; mean blood pressure evolution was instead evaluated graphically up to day 30.

这段将无器官衰竭生存天数列为预定义的次要终点，并明确要求 **“SOFA score 0–1 for each component”**。也就是说，任一分项达到 2，该日就不满足正文所述的无器官衰竭标准。

**④ 与这个定义相联系的已发表数值。**

位置：[结果补充材料 PDF 第 5 页，eTable 3 最前两行](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=5>)。

| 结果，单位为天 | 左西孟旦组，N＝101 | 安慰剂组，N＝104 | 中位数差及 95% CI |
|---|---:|---:|---:|
| 第 30 天时的无器官衰竭天数，中位数（IQR） | 12（0–21） | 14（0–23） | −2（−10 至 4） |
| 器官衰竭天数，中位数（IQR） | 9（6–17） | 12（6–18） | −3（−5 至 2） |

同表的[脚注 b 位于 PDF 第 6 页](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=6>)，完整说明为：

> Absolute difference between groups (difference in medians for continuous variables or in percentages for categorical variables), with a 95% confidence interval estimated by non-parametric bootstrap resampling.

因此，这里报告的是**中位数差及 bootstrap 置信区间**。C002 质疑的是这些数值对应的终点判定规则；现有证据没有建立它们自身的算术矛盾。

**2．差异具体落在哪里？**

考虑一个用于比较定义的例子：患者当天存活，六个 SOFA 分项为：

**（2，1，0，0，1，0）**

| 判定问题 | 结果 |
|---|---|
| 是否有分项 >2，达到 SAP 所述器官衰竭标准？ | 没有 |
| 是否每个分项都为 0–1，达到主文所述无器官衰竭标准？ | 没有 |

所以，这一天**不满足 SAP 的衰竭标准，也不满足主文的无衰竭标准**。

这里需要保留一个细节：SAP 没有另外逐字写出“无衰竭日＝所有分项 ≤2”。将它理解成上述衰竭定义的补集，是自然的阅读，但仍应与直接原文区分。

如果研究有意设置一个“既未达到 >2 的衰竭标准、又不计为无衰竭”的中间状态，两种规则可以分别使用；但**本次核对的定义段落、结果表注及图例，没有交代这种中间状态，也没有说明 2 分日实际怎样计入两个结局。** 这就是 C002 留下的实质问题。

**3．补充图能否解决这个边界？**

位置：[结果补充材料 PDF 第 12 页，eFigure 3](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=12>)。

我直接查看了图中的六个分项面板。图例明确区分 **0、1、2、3–4**，图中也能看到 2 分所占的比例。因此，2 是一个实际展示的独立类别。

不过，图展示的是各器官分项在第 1、7、14、21、28 天的**分别分布**，没有给出同一患者、同一天六个分项的联合记录。

例如，某患者肾脏分项为 2，如果当天呼吸分项已经为 3，那么这一天在两种规则下都不会是无衰竭日。**真正区分两种规则的，是至少一项为 2、同时没有任何分项 >2 的日子。** 图中存在 2 分，仍不足以确定这种患者日的数量。

**4．C002 在审查中经历了什么？**

现有记录中的处理链为：

- 跨来源检查产生 **F-XS-003**；第一次统计检查独立产生 **F-ST1-004**。
- 独立纳入筛查认定两者描述同一个阈值问题，合并登记为 **C002**，按 **Route B、focus D** 纳入。
- 直接证据复核确认了 SAP 两次出现的 **>2**、正文的 **0–1**，以及相应表格和图例，记录为 **`reproduced`**。
- 第二次统计检查继续保留该问题；质量审计记录为 **`CONFIRMED`**。

相关记录见：[候选台账](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/candidate_ledger.md)、[证据复核](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md)。

**C002 的 Review_domain 是 `protocol_report`，关系类型为 `P_R`。** 原因是比较发生在前瞻性 SAP 的终点规定与实际报告的终点描述之间。它虽然涉及统计结果，却不是记录中的 `statistical_results` 类别。

这里 `CONFIRMED` 表示符合候选纳入标准。C002 仍为 **`Pending Human Adjudication`**，没有确定实际程序采用了哪一个阈值。

**5．对后续分析和证据使用有什么影响？**

**首先，它可能改变患者层面的终点数值。** 在存活、观察窗口及缺失值处理相同的条件下，“所有分项 ≤1”比“所有分项 ≤2”更严格。满足“至少一项为 2、没有任何一项 >2”的日子，在前者下不能计为无衰竭日。

对于还会受到“死亡赋 0”规则影响的患者，需要先结合该赋值方式判断，不能只逐日相减。因此，重算需要患者逐日六分项数据、死亡信息、缺失评分规则以及实际终点代码。

**其次，不能由这个单向的日级变化，推断组间差异会向哪个方向改变。** 即便更严格的阈值使两组部分患者的无衰竭天数减少，两组减少的分布也可能不同。已报告的中位数差 −2 天可能改变，也可能维持；仅凭表中汇总数不能判断。

同理，若患者排序和分布发生变化，秩和检验、bootstrap 区间及相关模型结果也可能变化。**目前没有足够输入量化这些变化。**

**第三，无衰竭天数和衰竭天数的两行结果，不能直接当作“30 天减去另一行”。** 它们涉及死亡赋值及观察规则，而且组别中位数一般不满足相加关系。12＋9、14＋12 不等于 30，本身不能建立新的数值矛盾。

**第四，对系统综述，最直接的影响是终点是否可比。** 数据提取者可能给同一组“12 对 14 天”附上不同定义：一种允许分项 2，另一种要求每项均为 0–1。如果后续按 SOFA 阈值比较、分组或合并研究，这个区别会影响终点可比性的判断。统一成“无器官衰竭天数”这一名称，不能消除阈值差别。

**第五，目前不能把影响扩展到主要 ECMO 撤机结果。** C002 直接涉及器官衰竭相关次要终点，没有源证据表明它改变了主要终点的 sHR＝1.02，也不能据此认定论文主要结论发生变化。表中这两个中位数差的区间均包含 0；它们也不足以推断另一阈值下的结果。

**尚待明确的核心问题是：eTable 3 的无器官衰竭天数和衰竭天数，实际分别使用什么 SOFA 分项规则计算，尤其是“最高分项恰好为 2”的患者日被怎样处理？**

---

## User — C003 request

continue on C003, remember, stat terminologies should not be translated.

## Assistant — Progress update

我会继续核对 C003 的原始定义、计划中的分析和已报告结果，沿用前面的详细说明方式；统计术语保留英文。页面渲染使用 CPU，如需 OCR 也默认使用 CPU，你可以要求 GPU OCR。

## Assistant — Progress update

已确认 protocol、SAP 和主文的 endpoint 定义都包含 D30 与 D60，而对应结果表只给出 D30 的 ECMO-free days 和 ventilator-free days。我也逐一查看了补充材料的九个 eFigures；其中的 D60 mortality、MACE 和 ICU/hospital stay 均是其他 endpoints，不能补上缺少的 D60 free-day results。

## Assistant — C003 complete answer

**C003 涉及两个 prespecified secondary outcomes：D60 ECMO-free days 和 D60 ventilator-free days。Protocol、SAP 和主文都列出了 D30、D60 两个 windows，但所提供的结果表只给出 D30 results，未找到可明确对应 D60 的 summaries 或 treatment contrasts。**

我已重新核对原始 PDF，包括 protocol 的重复 endpoint 条目、SAP 的分析段落、主文及结果表，并逐一查看了补充材料的九个 eFigures。六份源 PDF 的 SHA-256 均与原审查记录一致。

需要保留一个区别：**论文确实有“free days 在两组间没有差异”的概括性叙述；C003 指向的是缺少可辨认的 D60-specific results，不能据此认定 D60 data 未收集或 analysis 未执行。** 以下统计术语保留英文。

**1．原始文件具体计划了什么？**

**① Protocol 明确列出 D30 和 D60。**

位置：[Protocol PDF 第 106 页，内部第 13/46 页，version 3.0，§4.1.2 Secondary endpoints](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=106>)。

该处分别列出：

> Total duration of ECMO support between inclusion and D30 and between inclusion and D60;  
> Number of ECMO-free days between inclusion and D30/D60.

同一列表还包括：

> Duration of mechanical ventilation and days alive without mechanical ventilation between inclusion and D30 and D60;

这说明计划中分别存在 **D60 ECMO-free days** 和 **D60 days alive without mechanical ventilation**，而不只是“随访至 D60”。

这些 windows 在不同 protocol versions 中重复出现，例如[原版本 PDF 第 15 页](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=15>)及[后续版本 PDF 第 60 页](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=60>)。本次也重新提取并检查了记录所列的全部九处：第 8、14、15、53、59、60、99、105、106 页。

**② SAP 不仅列出 endpoints，也规定了对应 analyses。**

位置：[SAP PDF 第 7 页，§3.6 Secondary endpoints analyses，“ECMO Support Duration”段落](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=7>)。

完整段落为：

> **ECMO Support Duration:** Total duration of ECMO support between inclusion and D30, and between inclusion and D60; and the number of ECMO-free days from inclusion to D30/D60 will be compared using the Wilcoxon rank sum test, with deaths imputed as 0 ECMO-free days. To adjust for the primary etiology of cardiogenic shock, a general linear model will be used.

位置：[SAP PDF 第 8 页，“Mechanical Ventilation”段落](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=8>)。

完整段落为：

> **Mechanical Ventilation:** Duration of mechanical ventilation and the number of ventilatory-free days between inclusion and D30, as well as between inclusion and D60, will be compared using the Wilcoxon rank sum test, with deaths imputed as 0 ventilatory-free days. To adjust for the primary etiology of cardiogenic shock, a general linear model will be used.

这两段提供了比较完整的 analysis specification：

- windows 包括 D30 和 D60；
- group comparison 使用 **Wilcoxon rank sum test**；
- deaths 对应的 free days 设为 0；
- 另计划使用 **general linear model**，对 cardiogenic shock etiology 进行 adjustment。

因此，C003 有具体的 planned analyses 作为比较对象。

**③ 主文仍然保留两个 windows。**

位置：[主文 PDF 第 3 页，印刷第 62 页，右栏上方 Outcomes 续段](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=3>)。

完整段落为：

> Predefined secondary outcomes included all-cause mortality at 30 days and 60 days; days alive without organ failure at day 30 (SOFA score 0-1 for each component); durations of ECMO and mechanical ventilation and ECMO- and ventilation-free days at 30 and 60 days (death counted as 0 days); duration of catecholamine support and days alive without it at day 30; duration of kidney replacement therapy and days alive without it at day 30; left ventricular ejection fraction by echocardiography at day 30; major adverse cardiovascular events (death, heart transplant, escalation to need for left ventricular assist device, stroke, dialysis, or heart failure rehospitalization) at days 30 and 60; and ICU and hospital lengths of stay. Time to hemodynamic improvement (mean blood pressure >60 mm Hg) was planned but not analyzed, as most patients remained stable; mean blood pressure evolution was instead evaluated graphically up to day 30.

这里明确写了 **“ECMO- and ventilation-free days at 30 and 60 days”**。因此，最终报告的 endpoint 定义本身也没有把这两个 D60 outcomes 移除。

段落末尾确实解释了另一个 outcome——time to hemodynamic improvement——为何没有进行原计划的 analysis；但这项说明针对的是该 outcome，不能用来解释 D60 free-day results 的缺失。

**2．实际报告了哪些 results？**

我直接核对了以下两处表格：

| Outcome 与来源 | Levosimendan，median（IQR） | Placebo，median（IQR） | Median difference（95% CI） |
|---|---:|---:|---:|
| ECMO-free days **by D30**，主文 Table 2 | 24（0–26） | 23（12–26） | 1（−1 至 4） |
| Days alive and free from MV **by D30**，eTable 3 | 6（3–11） | 6（3–13） | −0（−3 至 2） |

来源分别是：

- [主文 PDF 第 6 页，印刷第 65 页，Table 2：“No. of days free of ECMO by day 30”](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=6>)。
- [结果补充材料 PDF 第 5 页，eTable 3：“No of days alive and free from MV by day 30”](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=5>)。

表中的 **−0** 是原文显示形式，本身不构成这里的 reporting issue。

对应关系是：

| Outcome | Planned windows | 找到的对应 numerical results |
|---|---|---|
| ECMO-free days | D30、D60 | D30 |
| Ventilator-free days | D30、D60 | D30 |

**C003 没有指出这些 D30 numbers 自身不一致；它指出两个 D60 counterparts 未在 supplied reports 中出现。**

**3．有没有文字或其他图表已经提供 D60 results？**

这是本次独立核对中需要特别说明的部分。

[主文 PDF 第 7 页，印刷第 66 页，Discussion 第一段](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=7>)确实写道：

> In this double-blind, placebo-controlled RCT involving patients receiving VA-ECMO for severe but potentially reversible cardiogenic shock, early treatment with levosimendan was not associated with a shorter time to successful ECMO weaning. Survival at days 30 and 60; ECMO-, organ failure–, and mechanical ventilation–free days; and ICU length of stay were not different between groups.

这段有关于 free days 的总体结果陈述。不过，它没有分别标明 D30 与 D60 的 free-day results，也没有给出 D60 的 median、IQR、effect estimate、CI 或对应 test。句中的 “at days 30 and 60” 直接跟在 survival 后面，不能单靠这句话确定两个 free-day windows 分别进行了什么 analysis、得到什么结果。

因此，更准确的表述是：

**存在概括性 narrative，但缺少可单独识别、提取和核对的 D60 free-day outputs。**

我还检查了全部 32 页 supplied REPORT materials：主文 10 页、结果补充材料 18 页、collaborator roster 3 页和 data-sharing statement 1 页。补充材料中九个 eFigures 的图内内容也逐一查看了。以下 D60 outputs 确实存在，但对应其他 quantities：

- [结果补充材料第 11 页，eFigure 2](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=11>)：D30、D60 mortality。
- [第 13 页，eFigure 4](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=13>)：D30、D60 MACE。
- [第 16 页，eFigure 7](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=16>)：截至 D60 的 ICU/hospital stay distributions。

它们不能代替 D60 ECMO-free days 或 ventilator-free days。

**4．C003 在审查中如何被处理？**

现有审查链记录为：

- 跨来源检查产生 **F-XS-005**，第一次 statistical review 独立产生 **F-ST1-008**。
- 独立 inclusion screening 将二者合并为一个问题，登记为 **C003**。
- 纳入依据为 **Route A, category 5**：planned primary 或 key secondary analysis 未在 supplied reports 中报告。
- Evidence recheck 记录为 **`reproduced`**；第二次 statistical review 继续保留该问题；inclusion audit 记录为 **`CONFIRMED`**。

这里的 **key secondary** 来自本审查规则的操作性定义：出现在 abstract 中的 secondary outcomes 归入该范围。主文 [abstract 的 Main Outcomes and Measures 段](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=1>)确实列出了 ECMO-free 和 mechanical ventilation–free days；这不等于声称作者另行赋予了它们正式的 hierarchy 标签。

C003 的字段为：

| 字段 | 记录 |
|---|---|
| Review_domain | `protocol_report` |
| Relationship type | `P_R` |
| Evidence state | `reproduced` |
| Inclusion audit | `CONFIRMED` |
| 当前状态 | `Pending Human Adjudication` |

它属于 `protocol_report`，因为核心比较是 PLAN 中的 prespecified analyses 与 REPORT 中可找到的 outputs。`CONFIRMED` 表示符合候选纳入标准，并未确定缺失的原因。相关记录见[候选台账](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/candidate_ledger.md)和[证据复核](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md)。

**5．对 downstream analysis 和结果解读有什么影响？**

**首先，D30 results 不能代替 D60 results。** 两者具有不同的 observation windows。D31–D60 的死亡、再次接受 ECMO 或 mechanical ventilation，以及持续需要支持的时间，都可能影响 D60 free days。D30 median、IQR 和 median difference 没有包含足够信息来推导这些变化。

**也不能简单给 D30 free days 加 30。** 以一个假设情形说明：患者 D30 时存活且已脱离支持，但在 D45 死亡。若 D60 按该 window 内 deaths 赋 0，则该患者可有正的 D30 free days，却有 0 个 D60 free days。这个例子只解释 death assignment 为什么使简单外推不成立，不代表试验中某位患者的实际经历。

**其次，D60 mortality 无法补足 free-day distribution。** 即使知道 D60 死亡人数，仍不知道每位存活者的支持时长、是否重新接受支持，以及这些信息与死亡时间如何对应。仅凭 mortality、ECMO duration 的 group summaries，不能重建 D60 free-day median、IQR 或 treatment contrast。

**第三，primary endpoint 的确认随访延长至 D60，也不是 D60 free-day analysis。** Protocol 第 106 页说明：D30 前撤离 ECMO 的事件，还需撤机后 30 天随访确认成功，所以观察可延长至 D60。这里延长的是 **D30 successful-weaning event 的确认期**；它没有提供整个 D0–D60 window 的 free-day distribution。

**第四，对 systematic review 或 meta-analysis，缺少的是一个特定 window 的可提取结果。** 如果 synthesis 关注 D60 ECMO-free days 或 ventilator-free days，目前这份 package 没有相应的 effect estimate 与 precision information。把 D30 results 放入 D60 分组，会混合不同的 endpoint windows；将 D60 留为未提供，则需要保留这个 reporting gap。

**第五，不能从“未提供”推断 D60 的 treatment effect。** D30 的两个 95% CIs 均包含 0，但这不能推出 D60 effect 必然相同、必然较小或必然为 null。Discussion 的概括性陈述也不足以量化 D60 result。现有证据没有建立结果缺失与 effect direction、P value 之间的关系，也没有显示 C003 改变了已报告的 primary endpoint sHR＝1.02。

**目前仍待明确的是：prespecified D60 ECMO-free days 和 ventilator-free days 的 summaries、treatment contrasts 及对应 analyses 在哪里；或者，是否存在 supplied package 未包含的 documented revision，解释这两个 D60 outputs 的缺失。**

---

## User — C004 request

continue on C004

## Assistant — Progress update

我会继续核对 C004 的原始 SAP、相关 protocol 和结果表，重点确认 planned hierarchical composite 与已报告 LVEF result 分别代表什么，并分析 downstream impact。统计术语保留英文；页面渲染使用 CPU，如需 OCR 也默认使用 CPU，你可以要求 GPU OCR。

## Assistant — Progress update

我已在原始 SAP 中确认 planned analysis 是按 death → heart transplantation → LV function 排序的 hierarchical composite，并使用 Global Net Benefit。eTable 3 则报告 LVEF 的 median difference，且 footnote 明确规定：D30 前死亡者使用最后一次 pre-death LVEF。因此，两者涉及不同的 outcome quantity 和 death handling；现有证据还不能确定这行 LVEF result 是替代了 planned analysis，还是额外的 descriptive summary。

## Assistant — C004 complete answer

**C004 涉及 planned outcome 与 reported outcome 的区别：SAP 计划在 D30 使用包含 death、heart transplantation 和 LV function 的 hierarchical composite，并报告 Global Net Benefit；结果表提供的则是 LVEF 的 median、IQR 和 median difference。**

我已亲自查看新渲染的 SAP 第 8 页、结果补充材料第 5–6 页，并核对主文、protocol 及其他 supplied REPORT materials。六份源 PDF 的 SHA-256 均与原审查记录一致。

目前可以确认：**已报告的 LVEF contrast 不能代表 SAP 中的 hierarchical composite result。** 尚不能确定它是替代了 planned analysis，还是一个额外的 descriptive summary，而对应的 Global Net Benefit output 未随 package 提供。

**1．SAP 原本规定了什么？**

位置：[SAP PDF 第 8 页，“Left Ventricular Function”完整段落及后续规则](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=8>)。

该节首先规定：

> **Left Ventricular Function:** To compare the two treatment groups, we will use the Global Net Benefit method at Day 30, base on a hierarchical composite event:
>
> 1. Death  
> 2. Heart transplantation  
> 3. Left ventricular function improvement defined as achieving a left ventricular ejection fraction (LVEF) > 30%

随后说明每位 experimental-group patient 与每位 control-group patient 进行 pairwise comparison，并列出完整判定规则：

> Each patient in the experimental group will be pairwise compared to each patient in the control group:
>
> - A patient from the experimental group is considered a “win” if he survives while the matched control patient dies.
> - If both patients survive, a “win” occurs if the experimental group patient does not require heart transplantation while the control patient does.
> - If neither patient undergoes transplantation, the patient with greater left ventricular function improvement at Day 30 is considered the winner.
> - If both patients have the same outcome at each hierarchical level, the comparison is classified as a “tie”.

该节最后还规定：

> A positive Net Benefit value indicates a favorable effect of the experimental treatment compared to the control and 95% Confidence Interval of the Net Benefit will be estimated using bootstrap.

这套 analysis 的关键是 **hierarchy**：先按 survival 判定；在相应条件下再比较 transplantation；之后才进入 LV function 层级。最终需要汇总 pairwise wins、losses 和 ties，形成 Global Net Benefit。

另一个需要保留的细节是：第三层的文字同时提到 **LVEF >30%** 和 **greater LV function improvement**。具体 operational coding 不能由后面报告的 group medians 补定；但这不影响我们确认，SAP 明确计划了 death-first、transplant-second 的 hierarchical analysis。

**2．主文及结果表实际报告了什么？**

Protocol 将 D30 LV function 列为 secondary endpoint，例如[protocol PDF 第 106 页，§4.1.2](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=106>)写的是通过 echocardiography 评估 D30 LV function。这个较概括的规定，可以容纳 SAP 后续给出的详细 analysis specification，本身不构成 plan–plan conflict。

[主文 PDF 第 3 页，印刷第 62 页，Outcomes 段落](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=3>)则将这一 outcome 描述为：

> left ventricular ejection fraction by echocardiography at day 30

实际 numerical result 位于[结果补充材料 PDF 第 5 页，eTable 3 的 LVEF 行](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=5>)：

| Reported outcome | Levosimendan | Placebo | Median difference（95% CI） |
|---|---:|---:|---:|
| LVEF，median（IQR），by D30 | 45（30–50），n＝100 | 40（25–50） | 5（−0 至 10） |

Placebo column 的 arm size 为 104；该行没有另列较小的 n。

这里 **45−40＝5**，与打印的 median difference 相符。C004 没有指出这三个数之间存在 arithmetic discrepancy。

**真正关键的是下一页的 footnote：它说明死亡患者怎样进入这行 LVEF summary。**

位置：[结果补充材料 PDF 第 6 页，eTable 3 footnote a](</home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=6>)。

完整段落为：

> Summary measure within each group: median (interquartile range) for continuous variables, number and percentage (n (%)) for categorical variables. For patients alive at day 30, left ventricular ejection fraction (LVEF) was assessed at day 30 and for those who died before day 30, the last available LVEF measurement prior to death was used. In the presence of missing data, the number of observations is reported as (n = …) for continuous variables and as n/N (%) for categorical variables. Being free from cardiovascular failure was defined as a cardiovascular component of the SOFA score < 2.

紧接着，footnote b 说明：

> Absolute difference between groups (difference in medians for continuous variables or in percentages for categorical variables), with a 95% confidence interval estimated by non-parametric bootstrap resampling.

因此，这行 reported result 的具体含义是：

- D30 存活者使用 D30 LVEF；
- D30 前死亡者使用最后一次 **pre-death LVEF**；
- 对这些 LVEF values 计算 group medians、IQRs 和 median difference；
- CI 来自 non-parametric bootstrap。

**它不是一个仅包含 D30 survivors 的 summary，也没有通过 death-first hierarchy 来确定 pairwise wins 或 losses。**

**3．两种 analyses 为什么不能互相替代？**

| 比较维度 | SAP 中的 planned analysis | 已报告的 eTable 3 result |
|---|---|---|
| Outcome structure | Hierarchical composite | LVEF summary |
| Death 的处理 | 在 hierarchy 第一层决定 pairwise ordering | 使用最后一次 pre-death LVEF |
| Heart transplantation | Hierarchy 第二层 | 该 LVEF row 没有给出 transplant-priority rule |
| LV function 的作用 | 在相应 higher-priority comparisons 未决定结果后进入下一层 | 直接进入 LVEF distribution |
| Effect measure | Global Net Benefit | Median difference |
| Result 的尺度 | Pairwise wins/losses 所构成的 quantity | LVEF percentage points |

一个**假设例子**可以说明 death handling 的实质区别：

- Experimental patient 在 D30 前死亡，最后一次 pre-death LVEF 为 55%；
- Control patient 在 D30 存活，D30 LVEF 为 40%。

按 SAP 的第一层规则，这个 experimental patient 对应 **loss**，因为另一位患者存活。单看用于 LVEF summary 的两个 values，却是 **55% 高于 40%**。

这只是解释两种 outcome quantities 的逻辑区别，不代表试验中存在这样一对实际患者。它表明：**一个较高的 LVEF value，不必然对应 hierarchical composite 中较好的 outcome。**

Heart transplantation 的优先级也有类似作用：即使某人的 LVEF 较高，pairwise comparison 仍可能已经在 transplantation 层级决定。

**4．C004 在审查中经历了什么？**

现有记录中的处理链为：

- 跨来源检查产生 **F-XS-004**，第一次 statistical review 独立产生 **F-ST1-002**。
- 独立 inclusion screening 将二者合并为 **C004**。
- 纳入依据为 **Route A, category 5**，即 prespecified composite definition 与 supplied outcome presentation 不一致。
- Evidence recheck 记录为 **`reproduced`**；第二次 statistical review 继续保留该问题；inclusion audit 记录为 **`CONFIRMED`**。

这里的纳入依据是**明确的 hierarchical composite 与 LVEF-only presentation 之间的区别**，并非仅因为某个 non-key secondary model 没有提供结果。

| 字段 | 当前记录 |
|---|---|
| Review_domain | `protocol_report` |
| Relationship type | `P_R` |
| Evidence state | `reproduced` |
| Inclusion audit | `CONFIRMED` |
| 状态 | `Pending Human Adjudication` |

相关记录见[候选台账](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/candidate_ledger.md)和[证据复核](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/verification/evidence_recheck.md)。

本次独立核对支持这一有边界的描述：**supplied reports 提供了 LVEF contrast，未找到对应的 hierarchical composite／Global Net Benefit output。** 但“analysis 被替换”与“LVEF 是额外 summary，而 planned output 未提供”仍是两种尚未区分的解释。`CONFIRMED` 不代表已经确定了其中一种。

**5．对 downstream analysis 和结果解读有什么影响？**

**首先，不能把“median difference＝5”解释为 planned Global Net Benefit。** 这里的 5 对应 LVEF 的 **5 percentage points**，不是 5% relative effect，也不是 Global Net Benefit＝0.05。两者的 effect measure、尺度及 outcome definition 均不同。

**其次，不能据此认为 treatment 在包含 survival 和 transplantation 的整体 hierarchy 上更有利。** LVEF contrast 没有保留 SAP 对 death 和 transplantation 的优先排序。即使 LVEF median 较高，也不能确定 Global Net Benefit 的方向，更不能确定其 magnitude 或 CI。

**第三，不能从 medians 和 IQRs 重建 planned analysis。** 重建至少需要每位患者的 death status、transplantation status、相关 LVEF records，以及实际第三层和 tie rules，才能形成 pairwise comparisons。两个 group medians 不能提供这些组合信息；即使补上 group-level death 和 transplant counts，也不足以恢复全部 patient-level comparisons。

同样，**45% 与 40% 是 reported LVEF levels 的 medians**，不是 median change from baseline。它们也不能给出达到 **LVEF >30%** 的准确人数或比例。

**第四，reported CI 不能用作 Global Net Benefit 的 precision information。** 表中 CI＝−0 至 10 属于 LVEF median difference；SAP 计划中的 CI 属于 Global Net Benefit。两者即使都使用 bootstrap，也仍是不同 statistic 的 CI。打印的下界为 −0，不能只凭 point estimate＝5 就作出 statistical significance 判断，更不能推断 planned hierarchical analysis 的 significance。

**第五，对 systematic review 或 meta-analysis，最直接的影响是 outcome 与 effect measure 的提取。** 如果后续研究关注 LVEF，可以提取这行结果，但需同时保留它的 measurement rule：survivors 用 D30 LVEF，decedents 用 last pre-death LVEF。若关注 SAP 所定义的 hierarchical composite，这行 median difference 不能作为其 effect estimate；否则会把不同的 outcomes 当成同一 quantity。

**目前没有源证据表明 C004 改变了已报告的 primary endpoint sHR＝1.02。** 尚待明确的问题是：**planned death／transplantation／LV-function hierarchical analysis 是否执行，其 Global Net Benefit 和 CI 在哪里，以及 reported LVEF summary 与这项 planned analysis 之间是什么关系，或是否存在 documented amendment。**

---

## User — Export request

save the conversation into a md file and put it under the ./review_records/*

## Assistant — Progress update

I’ll save the visible conversation as a Markdown transcript under `review_records/`, preserving the Chinese explanations, English statistical terms, and source links.

## Assistant — Progress update

The transcript now includes the complete C001 and C002 exchanges. I’m adding C003 and C004, then checking completeness and source-link targets.

## Assistant — Export confirmation

Saved the full conversation to [conversation_C001_C002_C003_C004.md](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/review_records/conversation_C001_C002_C003_C004.md).
